Clinical Trial Update: A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of JNJ-31001074 in Pediatric Patients (12-17 Years) With Attention Deficit Hyperactivity Disorder (ADHD) [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating pharmacokinetics, safety and tolerability of a single dose of JNJ-31001074 in pediatric patients aged 12-17 with ADHD has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• JNJ-31001074

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity | Phase 1 | Status: COMPLETED